Rockefeller Capital Management
LXEO icon

Rockefeller Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

Rockefeller Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$698 Sell
150
-991
-87% -$5.36K ﹤0.01% 4564
2026
Q1 		$6.55K Buy
1,141
+441
+63% +$3.13K ﹤0.01% 4158
2025
Q4 		$6.95K Buy
700
+500
+250% +$4.56K ﹤0.01% 3952
2025
Q3 		$1.33K Buy
+200
New +$967 ﹤0.01% 4146

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Rockefeller Capital Management's LXEO Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Lexeo Therapeutics (LXEO) stake by 87% in Q2 2026, selling an estimated $5.36K and leaving 150 shares worth $698. The position accounts for ﹤0.01% of the portfolio, ranked #4564.

Rockefeller Capital Management first reported a position in LXEO in Q3 2025 and has held it in 4 quarters since. The position peaked at $6.95K in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Rockefeller Capital Management held 150 shares of Lexeo Therapeutics worth $698 as of Q2 2026.
  • Rockefeller Capital Management sold 991 Lexeo Therapeutics shares in Q2 2026, an estimated $5.36K.
  • Lexeo Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4564 holding.
  • Rockefeller Capital Management first reported a position in Lexeo Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Rockefeller Capital Management's Lexeo Therapeutics position peaked at $6.95K in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.